November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
20 citations
,
March 2017 in “Arthritis research & therapy” Social media can help compare the effectiveness and safety of new arthritis medications.
15 citations
,
April 2022 in “Immunology” Men and women get COVID-19 at similar rates, but men tend to get sicker and have a higher risk of dying, while women usually have stronger immune responses and vaccine reactions.
7 citations
,
July 2024 in “Frontiers in Immunology” COVID-19 can increase the risk of hair loss, especially in people over 40.
4 citations
,
January 2023 in “Skin Pharmacology and Physiology” Turpentine ointment is effective and safe for treating folliculitis.
4 citations
,
February 2022 in “Journal of Cosmetic Dermatology” Monocytes might be linked to hair loss after COVID-19.
1 citations
,
June 2023 in “JAAD case reports” Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
December 2025 in “Rare Metals” Smart biomaterials and dressings show promise in treating chronic skin diseases by improving drug delivery and minimizing side effects.
March 2025 in “Dermatology” Systemic therapies improve nail psoriasis but have high side effects; more research is needed.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.